Candel Therapeutics, Inc. (CADL)
| Market Cap | 641.99M +130.7% |
| Revenue (ttm) | n/a |
| Net Income | -88.53M |
| EPS | -1.44 |
| Shares Out | 76.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,642,567 |
| Open | 9.11 |
| Previous Close | 9.22 |
| Day's Range | 8.34 - 9.21 |
| 52-Week Range | 4.35 - 14.00 |
| Beta | -0.29 |
| Analysts | Strong Buy |
| Price Target | 22.11 (+163.53%) |
| Earnings Date | Nov 12, 2026 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price target is $22.11, which is an increase of 163.53% from the latest price.
News
Candel Therapeutics says in ongoing dialogue with FDA on aglatimagene BLA
The company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application for aglatimagene in prostate cancer. Due to timelines associated with certain assay refineme...
Candel Therapeutics reports Q3 EPS (28c), consensus (31c)
Cash and cash equivalents, as of September 30, 2026, were $203.1 million compared to $119.7 million as of December 31, 2025. Based on current operating plans, the Company expects that…
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Earnings release: Q3 2026
Candel Therapeutics released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Candel Therapeutics Quarterly report: Q3 2026
Candel Therapeutics has published its Q3 2026 quarterly earnings report on November 12, 2026.
Candel Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
PrTK05 biomarker results support systemic immune activation after local prostate treatment, alongside Phase III disease-free survival success and favorable exploratory findings. NSCLC Phase III plans incorporate learnings from Phase II, while payer research points to a potential $285,000 median annual GU price range for three administrations.
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (...
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics to Present at November Investor Conferences
NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $25 price target The company’s positive Phase III prostate data for CAN-2409 support a Q4…
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel announces final phase 2a trial of aglatimagene, valacyclovir
Candel Therapeutics (CADL) announced the publication of final phase 2a clinical trial results of aglatimagene besadenovec plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate...
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics announces data from phase 2 PrTK05 trial
Candel Therapeutics (CADL) announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial in patients with intermediate-risk localized prostate cancer. These data, together with hi...
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics announces new data on aglatimagene besadenovec
Candel Therapeutics (CADL) announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk ...
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics upgraded to Buy from Neutral at BofA
BofA upgraded Candel Therapeutics (CADL) to Buy from Neutral with a price target of $18, up from $12. A mature prostate cancer package, on track for a BLA in Q4,…
Candel Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two viral immunotherapies are advancing, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned by year-end. Commercial launch will target top accounts, with positive payer feedback and a focus on integrating into radiation workflows. Key upcoming milestones include biomarker data and regulatory filings.
Candel Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Viral immunotherapy programs are advancing, with aglatimagen showing significant efficacy in prostate cancer and moving toward BLA submission. Manufacturing and regulatory milestones are on track, with new biomarker and long-term survivor data expected by year-end.
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics to Present at September Investor Conferences
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...